Pieter Stolk

Dr. Pieter Stolk has a PharmD degree (2003) and PhD degree (2008) from Utrecht University, The Netherlands. After finishing his PhD, he worked in a strategy & business development position at a Dutch Public-Private Partnership (TI Pharma). Since 2010 he works as an independent consultant and also continues to be affiliated with Utrecht University (The Utrecht/WHO Collaborating Centre for Pharmaceutical Policy and Regulation). He works for NGOs, governments, companies and research organizations in the life sciences field. In 2013 he was one of the authors of the update of the WHO Priority Medicines Report. For the Priority Medicines Report, Pieter coordinated/co-authored, among others, chapters on new approaches to promoting innovation, including: public-private partnerships, regulatory structures to support pharmaceutical innovation, pricing and reimbursement arrangements, real-life data and learning from practice, and patient and citizen involvement. All these chapters included extensive stakeholder involvement and were authored by a team of international experts. One of his interests is how PPPs can operate effectively and how they can be used as a tool to promote pharmaceutical innovation that addresses public health needs. A current key activity is his role as a project manager for the IMI GetReal consortium: GetReal aims to improve the efficiency of the medicine development process by better incorporating real-world evidence into clinical study design and regulatory/HTA decision-making (www.imi-getreal.eu). In addition, he is involved in IMI ADAPT SMART project (www.adaptsmart.eu), this is an enabling platform for the coordination of Medicines Adaptive Pathways to Patients (MAPPs) activities. MAPPs seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span in a sustainable fashion.